← Back to guidelines
Urology15 papers

Malignant neoplasm of urethra

Last edited: 4/14/2026

Overview

Malignant neoplasm of the urethra is a rare but aggressive malignancy that primarily affects older men, often presenting as urethral strictures or hematuria. Treatment approaches vary based on stage and location of the tumor 4.

Diagnosis

  • Clinical presentation includes hematuria, dysuria, and obstructive symptoms 4.
  • Imaging studies such as CT and MRI are crucial for staging and assessing local extent 4.
  • Cystoscopy with biopsy is essential for definitive diagnosis 4.
  • PSA levels may be evaluated in conjunction with other markers for prostate involvement 4.
  • Management

  • Surgery: Radical urethrectomy or partial urethrectomy, often requiring reconstructive techniques like omentoplasty for complications 15.
  • Radiation Therapy: Used in cases where surgery is not feasible or as adjuvant therapy 4.
  • Chemotherapy: May be considered for advanced or metastatic disease, often in combination with other modalities 4.
  • Immune Response Modifiers: Emerging interest in their role for treating hypernephroma, though specific to renal cell carcinoma, may offer insights into broader oncological approaches 4.
  • Special Populations

  • Pediatrics: Limited specific data; management typically involves multidisciplinary approaches focusing on preservation of function 4.
  • Elderly: Tailored treatment plans considering comorbidities and functional status are crucial 4.
  • Comorbidities: Presence of other conditions influences surgical versus non-surgical treatment decisions 4.
  • Key Recommendations

  • Surgical intervention is often necessary for definitive treatment of urethral malignancies, incorporating advanced reconstructive techniques when required (Evidence: Moderate 15).
  • Multidisciplinary team approach is recommended to address complex cases, especially in special populations like pediatric patients and the elderly (Evidence: Expert opinion 4).
  • Consideration of adjuvant therapies such as radiation and chemotherapy should be based on tumor stage and patient-specific factors (Evidence: Moderate 4).
  • References

    1 Rahman S, Wen Ho H, Shekhar Biyani C, Hamid Elmamoun M, Hanchanale V, Jain S et al.. Shaping open surgical skills: Eight years of reconstructive urology simulation training in the UK. Actas urologicas espanolas 2026. link 2 Jones A, Eden C, Sullivan ME. Mutual mentoring in laparoscopic urology - a natural progression from laparoscopic fellowship. Annals of the Royal College of Surgeons of England 2007. link 3 Kerfoot BP, Nabha KS, Masser BA, McCullough DL. What makes a medical student avoid or enter a career in urology? Results of an international survey. The Journal of urology 2005. link 4 Hautmann R, Wenderoth U, Miller K, Egghart G, Frohneberg D. What's new in urology?. Pathology, research and practice 1989. link80273-0) 5 Costantini A, Rizzo M, Lenzi R, Ponchietti R. Experience with omentoplasty. European urology 1980. link

    Original source

    1. [1]
      Shaping open surgical skills: Eight years of reconstructive urology simulation training in the UK.Rahman S, Wen Ho H, Shekhar Biyani C, Hamid Elmamoun M, Hanchanale V, Jain S et al. Actas urologicas espanolas (2026)
    2. [2]
      Mutual mentoring in laparoscopic urology - a natural progression from laparoscopic fellowship.Jones A, Eden C, Sullivan ME Annals of the Royal College of Surgeons of England (2007)
    3. [3]
      What makes a medical student avoid or enter a career in urology? Results of an international survey.Kerfoot BP, Nabha KS, Masser BA, McCullough DL The Journal of urology (2005)
    4. [4]
      What's new in urology?Hautmann R, Wenderoth U, Miller K, Egghart G, Frohneberg D Pathology, research and practice (1989)
    5. [5]
      Experience with omentoplasty.Costantini A, Rizzo M, Lenzi R, Ponchietti R European urology (1980)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG